Meta-analysis has been widely used to synthesize information from related studies to achieve reliable findings. However, in studies of rare events, the event counts are often low or even zero, and so standard meta-analysis methods such as fixed-effect models with continuity correction may cause substantial bias in estimation. Recently, Bhaumik et al. developed a simple average estimator for the overall treatment effect based on a random effects model. They proved that the simple average method with the continuity correction factor 0.5 (SA_0.5) is the least biased for large samples and showed via simulation that it has superior performance when compared with other commonly used estimators. However, the random effects models used in previous work are restrictive because they all assume that the variability in the treatment group is equal to or always greater than that in the control group. Under a general framework that explicitly allows treatment groups with unequal variability but assumes no direction, we prove that SA_0.5 is still the least biased for large samples. Meanwhile, to account for a trade-off between the bias and variance in estimation, we consider the mean squared error to assess estimation efficiency and show that SA_0.5 fails to minimize the mean squared error. Under a new random effects model that accommodates groups with unequal variability, we thoroughly compare the performance of various methods for both large and small samples via simulation and draw conclusions about when to use which method in terms of bias, mean squared error, type I error, and confidence interval coverage. A data example of rosiglitazone meta-analysis is used to provide further comparison.
Introduction
Meta-analysis, a useful statistical procedure to synthesize information across a collection of relevant studies, has been widely used to obtain reliable findings in medical research. 1, 2 In this paper, we focus on meta-analysis of rare binary events to evaluate treatment/intervention effects between two experimental conditions by combining data from multiple clinical trials.
In many applications, the number of events of interest can be very low or even zero, mainly because the background incidence rate of the event is low and/or the sample size is not sufficiently large. For example, when the hormone replacement therapy is used to alleviate menopausal symptoms, it could cause serious diseases such as breast cancer and heart disease. These adverse events are rare but important to study. 3 It is evident that reliably detecting such adverse effects from an individual study is difficult. Thus, meta-analysis of rare binary events has been found to be useful and so received a lot of attention in the past.
Suppose there are K independent studies, in each of which there are treatment and control groups, and the outcome variable is binary. The whole data include K independent 2 Â 2 tables. Under this simple setup, various meta-analysis approaches have been developed to estimate treatment effects on binary outcomes, based on either fixed effect (FE) or random effects (RE) models. FE models assume treatment effects to be the same across all studies. Popular FE meta-analysis methods of binary events include the Mantel-Haenszel (MH) method, 4 the empirical logit (EL) method, 5 and Peto's method. 6 On the contrary, RE models allow the treatment effects to vary from study to study. Among many, DerSimonian and Laird 5 proposed the classical DerSimonian and Laird (DSL) method with weights depending on the within and between-study variance estimates.
When the focus is narrowed down to rare binary events, early attention was largely paid to the FE meta-analysis approaches. 7, 8 For rare binary events, ordinary estimators of the (log) odds ratio and (log) relative risk are often undefined or unstable. A commonly used approach to deal with this problem is adding a continuity correction factor. Sweeting et al. 7 found that the MH method performed better than the inverse-variance weighted method (i.e. the EL method) for imbalanced group sizes under all kinds of continuity correction. Bradburn et al. 8 compared the performance of 12 methods such as the MH method without zero-cell correction and logistic regression for pooling rare events. Both recommended the MH method with an appropriate continuity correction when analyzing sparse data with homogeneous treatment effects.
In practical situations, the FE assumption can be restrictive, where RE models are more appropriate. Through a specific rosiglitazone example involving rare binary events, Shuster et al. 9 showed meta-analysis based on RE models was superior to that based on FE models. Cai et al. 10 proposed likelihood methods based on Poisson RE models. More recently, based on a RE model, Bhaumik et al. 1 developed a simple average (SA) estimator, which, as will be seen in equations (3) and (4), simply takes the average of the estimated treatment effects (i.e. log odd ratios with a positive continuity correction factor a) from individual studies. Bhaumik et al. 1 set a ¼ 1 2 so that the estimator is proved to be asymptotically unbiased. They further compared the SA estimator with a ¼ 1 2 (SA_0.5) to commonly used estimators including MH, EL, and DSL via extensive simulation and a data example, and concluded SA_0.5 was the least biased and performed better than the competitors. Due to its competitive performance as well as simplicity, SA_0.5 appears to be the most compelling method for meta-analysis of rare binary events, among many.
However, Bhaumik et al. 1 only used the bias measure to develop SA_0.5 and evaluate the performance of the different estimators, and so did not account for a trade-off between the bias and variance in estimation. In addition, they did not consider small sample sizes in their simulation where the asymptotic unbiasedness of SA_0.5 might not hold. More importantly, the RE models used in Bhaumik et al. 1 and other existing work 11 are restrictive because they all assume that the variability in the treatment group is equal to or always greater than that in the control group.
In this paper, we first propose a framework for RE models, which explicitly allows treatment groups with unequal variability but assumes no direction. Under this general framework, we prove that SA_0.5 is still the least biased for large samples. Meanwhile, to account for a trade-off between the bias and variance in estimation, we consider the mean squared error (MSE) to assess the estimation efficiency, and show that SA_0.5 cannot achieve the optimal MSE of its kind. Under a new RE model that accommodates groups with unequal variability, we thoroughly compare the bias and MSE of various methods for both large and small samples via simulation; and their performance on hypothesis testing and interval estimation is further compared using the type I error and coverage of 95% confidence intervals (CIs). A data example of rosiglitazone meta-analysis is used for comparison as well. Based on results of simulation and real data analysis, we provide practical guidelines for meta-analysis of rare binary events under the general framework.
A general framework for RE models
Consider a meta-analysis including K independent studies. Throughout this paper, we assume K is a fixed constant. In the kth study, the treatment group includes n kt subjects, and the control group includes n kc subjects. Let x kt and x kc be the number of events of interest, and p kt and p kc be the probability of the event being observed in the treatment and control groups of the kth study, respectively, where x kt $ Binomialðn kt , p kt Þ, and x kc $ Binomialðn kc , p kc Þ. We denote the treatment effect of the kth study by k , which is defined by the log odds ratio k ln p kt =q kt p kc =q kc where q kt ¼ 1 À p kt and q kc ¼ 1 À p kc . Our general framework for RE models requires a minimal set of assumptions:
(1) The treatment effects k 's are random and follow an unknown distribution Dð, 
where any two components of ð 1 , . . ., K ; 1 , . . ., K Þ are assumed to be independent. This model implicitly assumes that the variance of logitð p kc Þ is not greater than the variance of logitð p kt Þ. Bhaumik et al. 1 further assumed k u in their simulation evaluation, where is a constant. Also, the model used in Smith et al. 11 assumes the equality of the variances, which is given by
By contrast, our general framework does not imply the equality or any specific direction between the variances of the treatment and control groups.
3 Properties of SA_0.5 under the general framework
As mentioned in ''Introduction'' section, Bhaumik et al. 1 considered the SA estimator a , namelŷ
where ka is an estimator of the treatment effect k given bŷ
with a constant a 2 ð0, 1 for continuity correction. They proved that a is asymptotically unbiased when a ¼ 1 2 under the specific RE model (1). Below we examine properties of the SA estimator under the RE framework proposed in ''A general framework for RE models'' section. We show that the asymptotic unbiasedness of SA_0.5 still holds but SA_0.5 fails to achieve the optimality in terms of minimizing the MSE of a .
Estimation bias
Gart et al. 12 showed that for any binomial random variable x, based on a sample of size m with parameter p, the following equation holds
where q ¼ 1 À p. Based on equation (5), we have the following conditional means for
be the overall minimum number of subjects, and let p ¼ ð p kt , p kc Þ K k¼1 . Under our general framework, we can have
That means, if n is large enough so that the higher order term Oðn À2 Þ can be ignored, SA_0.5 is an asymptotically unbiased estimator, i.e. lim n!þ1 Biasð1 2 Þ ¼ 0 under our general framework.
MSE
To derive the MSE of the SA estimator a under our general framework, we first consider the variance of a . For any binomial random variable x, based on a sample of size m with parameter p, we can show
where Vð f ðxÞÞ denotes the variance of f(x). Based on the above result, we have the following conditional variance
Combined with the bias of the SA estimator, we can get
As n ! þ1, we can ignore the higher order term Oðn À2 Þ. Thus, to minimize the MSE of the SA estimator for large n, the best choice of a in ð0, 1 is given by
where is an arbitrarily small positive number. Obviously, the SA estimator with a ¼ 1 2 cannot achieve the minimum MSE for large n except for the case
, where the choice of a does not matter at all (i.e. any number in ð0, 1 would minimize the approximate MSE).
A simulation-based comparative study
Under our general RE framework, we conducted simulation to address the following research questions for meta-analysis of rare binary events: (i) whether the superiority of SA_0.5, as shown in Bhaumik et al., 1 remains valid; and (ii) how various existing methods perform in terms of both bias and MSE, especially for small sample sizes. To do so, we first proposed a new RE model that accommodates groups with unequal variability. Using data simulated from this model, we compared the performance of various methods in estimating the overall treatment effect for both large and small samples. Here, a large sample case means that the Oðn À2 Þ term can be ignored compared to Oðn À1 Þ; otherwise, we call it a small sample case. To evaluate the performance of each estimator, we examined both bias and MSE.
As pointed out by one of the reviewers, the empirical performance of these methods on hypothesis testing and interval estimation is important as well. Thus, we also examined the type I error under the null hypothesis H 0 : ¼ 0 and the coverage of the corresponding 95% CI for each method.
A new RE model allowing for unequal group variability
We consider the following RE model
Þ and w is a constant which belongs to 0, 1 ½ . All k s and k s are assumed to be independent. Based on the RE model, we have
So we can control the sign of the difference in the variance of the logit between the control and treatment groups by the constant w: 0 w 5 1 2 means the variance of the logit in the treatment is greater than that in the control; w ¼ 1 2 means equal variances; and 1 2 5 w 1 means the variance in the treatment is less than that in the control. Meanwhile, the covariance between logitð p kc Þ and logitð p kt Þ also depends on the constant w, and it can achieve the maximum value 2 when w ¼ 0 or 1, and achieve the minimum value This new RE model fits in the general framework outlined in ''A general framework for RE models'' section; and it is more flexible than the RE model (1) in Bhaumik et al. 1 because it allows for unequal group variability without assuming any specific direction. Further, when w ¼ (7) is reduced to the model (2) used in Smith et al.
Methods to be compared
In our comparison, we first include all the four methods evaluated in Bhaumik et al. 1 's simulation: SA_0.5, MH, EL, and DSL. According to equation (6) , to achieve smaller MSE, we include the SA estimator with other correction factors a ¼ 1 and a ¼ 0.25, denoted by SA_1 and SA_0.25, respectively. Note that a ¼ 0.25 was recommended by Hitchcock 13 and Gart and Zweifel 14 for estimating the log odds ratio in an individual study, which was proposed based on the minimum logit 2 method. Also included is another popular estimator based on generalized linear mixed models (GLMM 15 ), which has been reported to work well in a wide range of applications including rare binary events. 16, 17 In addition, we consider an integrative median unbiased estimator, labeled iMUE, which is described below.
For any binomial random variable x, based on a sample of size m with parameter p, Parzen et al. 18 proposed
where FðÁj, Þ is the cumulative distribution function of a beta distribution with parameters and . Based on the MUE estimator of p, MUE:k can be defined as the estimator of the treatment effect k in the kth studŷ
wherep kt ¼pðx kt , n kt Þ is the MUE of p kt andp kc ¼pðx kc , n kc Þ is the MUE of p kc . Note that MUE:k always exists. In our meta-analysis of rare binary events, it is natural to define iMUE by iMUE ¼ P K k¼1 MUE:k =K.
Simulation settings
We consider meta-analysis of K 2 f10, 20, 50g independent studies of rare binary events. We generated the responses x kc and x kt from Binomialðn kc , p kc Þ and Binomialðn kt , p kt Þ, respectively, for k ¼ 1, . . . , K, where n kt ¼ R k Á n kc and ð p kc , p kt Þ satisfies equation (7). We set 2 À1:5, À 1:0, . . . , 1:5 f g , ¼ À5 (i.e. 0.0067 in the probability magnitude), and R is selected to approximately equal the sample standard deviation of the sample ratios in real data analysis in ''Example: Rosiglitazone metaanalysis'' section. Here, we restrict our attention to R > 1, because the two settings ðR, , wÞ and ð1=R, À , 1 À wÞ are the same except for group label switching, and so have exactly the same performance.
We generated n kc s from Uniform½2000, 3000 to examine large sample performance, and from Uniform ½20, 1000 to examine small sample performance, and rounded random draws to the nearest integers. Note that the above ranges for large and small samples were chosen based on preliminary simulation outcomes as well as theoretical arguments. Based on results in Gart et al., 12 we know that the Oðn À2 Þ term can be ignored when minðn kc p kc , n kt p kt Þ K k¼1 is not small, and at least it should be larger than 1 since Oðn À2 Þ may be larger than Oðn À1 Þ if it is not. Thus, for small sample sizes, we choose ½20, 1000 so that the empirical means of minðn kc p kc , n kt p kt Þ K k¼1 in all our settings are below one. Besides, in real meta-analysis datasets 7, 8, 19 that are treated as small sample cases, most sample sizes of individual studies are small, but a few sample sizes are around 1000. That's why we choose a large upper bound 1000 for small sample sizes. For large sample sizes, we find that further increasing either the upper or lower bound would lead to exactly the same conclusions as reported below.
Results based on bias and MSE
For each setting, we simulated 1000 datasets to compute the empirical bias and MSE of all the methods. We further calculated log2 relative efficiency (Re) based on MSE, where we set GLMM as the benchmark.
For a specific method, the Re is defined as the MSE of GLMM divided by the MSE of the method, where log 2 Re 4 0 means that it is more efficient than GLMM.
We use nested loop plots for visualization, which can efficiently present results from a large number of simulation scenarios. 20 We first need to figure out a reasonable lexicographical order of all P ¼ 4 parameters, including the mean treatment effect , the constant w, the sample size ratio R between the treatment and control, and the number of studies K, among the P! ¼ 24 possible orders. We find that the influences of and w are much larger than those of R and K. So the lexicographical order we choose is to sort (1) , (2) w, (3) R, and (4) K.
Large-sample results:
In the Supplementary Material, Figure S1 reports the bias and MSE for different methods over all the 189 simulation scenarios with large sample sizes. As the smallest unit of these figures shows, the no. of studies K does not affect the choice of methods in most scenarios. Thus, we use K ¼ 50 as an example to compare the bias and MSE of the eight different methods. Figure 1 (a) shows bias comparison using results from the 63 simulation scenarios for K ¼ 50 and large sample sizes. We find that the effect of the ratio R on comparing bias of different methods is marginal. Overall, SA_0.5 works the best in terms of bias, which is consistent with our theoretical result that SA_0.5 is asymptotically unbiased under the general framework. The second and third best methods are iMUE and SA_0.25, and both of them yield estimates that are only slightly biased. They are followed by GLMM and SA_1, which form the middle group. The bottom group contains DSL, EL, and MH, which are plotted separately from the others for better visualization, whose bias values are typically much larger. Among them, MH severely overestimates for cases of w ¼ 0 and underestimates for w ¼ 1; but it performs well for w ¼ 0.5 (i.e. equal group variability). DSL underestimates when 4 0 and overestimates when 5 0 except for cases with 4 0 and w ¼ 0 or cases with 5 0 and w ¼ 1, where it is nearly unbiased.
In Figure 1 (b), we compare MSE for K ¼ 50 and large sample sizes based on log 2 Re, where the yellow horizontal line at y ¼ 0 represents GLMM. We find that EL and MH are the worst two methods, typically having much larger MSE than the other methods. DSL can be bad for cases with large positive and w ¼ 1 or cases with large negative and w ¼ 0. Overall, SA_0.5 seems to be the most efficient estimator because it is the best in some settings (e.g. 4 0 and w ¼ 1) and is always among the top group otherwise. In addition, the performance of iMUE and SA_0.25 is pretty close to the top in nearly all the settings; SA_1 is the most efficient when ¼ 0 and À 0.5. 
Small sample results:
Bias and MSE results for all the 189 scenarios with small sample sizes are shown in Figure S2 of the Supplementary Material. Again, K seems not to affect the choice of the methods, and so we use the results for K ¼ 50 for comparison. As shown in Figure 2 (a), the ratio R has little impact on the relative performance of the different methods based on bias. Thus, we summarize the least biased method(s) by w and in Table 1 . We note that SA_0.25 performs consistently well in all the settings. Although it is not chosen as the best for settings with w ¼ 0, its performance is quite close to the best method(s) and much better than some of the other methods. Figure 2 (b) displays MSE comparison for small sample sizes based on log 2 Re. Unlike bias comparison, we find that R plays a role in evaluating the different methods. So in Table 2 , we report the most efficient method(s) by , w, and R, where the method(s) in the parenthesis is the second best and has performance very close to the best one.
Results based on type I error and coverage of 95% CIs
We examined the type I error of each method for testing the null hypothesis H 0 : ¼ 0 at the significance level 0.05 by simulating data from various null settings (with ¼ 0). As in Bhaumik et al., 1 we used the following statistic for testing H 0 : T ¼= c SEðÞ, where stands for an estimator of , and c SEðÞ is the estimated standard error (SE) of. We also used the methods described in Bhaumik et al. 1 to estimate the SEs of SA_0.5, DSL, EL, and MH. For SA_0.25, SA_1 and iMUE, we used the delete-d jackknife method 21 with d ¼ 2 to estimate the SEs. For GLMM, we used the output for the SE from an R package named lme4. 22 We then performed a t-test with the number of degrees of freedom df ¼ K À 1 for all the methods, except for SA_0.5, for which we performed a z-test instead. This is because when K is not large, the t-test works better than the z-test for all the methods but SA_0.5. The type I error rate of each method under each setting was empirically computed as the proportion of rejecting H 0 among 2000 replicates.
To further evaluate the coverage rate of 95% CIs for each method, we computed the proportion of the CIs that contain the true value among 2000 replicates under each setting. The CIs of SA_0.5 were computed using the z-test, i.e. AE 1:96 c SEðÞ; the CIs of the other methods were computed using the t-test, i.e. AE t 0:025,KÀ1 c SEðÞ, where t 0:025,KÀ1 is the critical value of the t distribution with df ¼ K À 1.
Due to the limited space, tables and figures for results based on type I error and coverage of 95% CIs are put in Sections S2 and S3 of Supplementary Material, along with a detailed description and a thorough discussion. Below we provide a brief summary about the performance for large and small samples, respectively.
Large-sample results:
As shown in Table S1 of Supplemental Material, SA_0.5, SA_0.25, SA_1, and iMUE perform better than the other methods for large sample sizes in terms of the type I error; their rates are close to the nominal level 0.05. As shown in Figures S3 to S5 , SA_0.5, SA_0.25, and iMUE form the top performing group in terms of the 95% CI coverage, and they provide coverage rates close to 95%. The performance of EL and MH is consistently poor in terms of both measures.
Small-sample results:
From Table S2 and Figures S6 to S8 , it appears that SA_0.25 is the best and iMUE is the second best, followed by SA_0.5, for small sample sizes in terms of both type I error and CI coverage; they can provide rates pretty close to the targeted level (0.05 or 95%) in most settings. Also, SA_1, DSL, EL, and MH do not perform well in general, among which EL and MH seem to be the worst two; GLMM does not perform well when w ¼ 1.
Example: Rosiglitazone meta-analysis
Rosiglitazone was a widely used drug to treat hyperglycemia in patients with type 2 diabetes mellitus. However, the use of rosiglitazone therapy has decreased dramatically as it might increase the risks of myocardial infarction (MI) and cardiovascular death (CVD). In order to evaluate potential adverse effects of rosiglitazone, Nissen and Wolski 19 conducted a meta-analysis of 48 randomized trials (the data depicted in Table S1 of the Supplementary Material), including the 42 studies they analyzed as well as six additional studies excluded from their analysis because of all zero counts for both MI and CVD events. In our meta-analysis, we applied the eight methods, namely SA_0.25, SA_0.5, SA_1, iMUE, GLMM, DSL, EL, and MH, to synthesize all the 48 trials, which include Table 2 . MSE comparison: the most efficient methods for small sample sizes based on simulation. Table 3 summarizes results from the different methods for the MI data, including the estimated treatment effect, estimated odds ratio (OR), and 95% CI of OR. We used the same methods described in ''Results based on bias and MSE'' section to compute the CI of each method. From Table 3 , we find that all the methods except for SA_1 report positive estimates of the mean treatment effect ; all except for MH provide CIs of OR that include 1, and so conclude that the effect of rosiglitazone on MI is not statistically significant. To understand the above results better, we conducted an exploratory analysis of the MI data. We estimated the log odds for each group of study k using kt ¼ lnðx kt þ 0:5Þ=ðn kt À x kt þ 0:5Þ and kc ¼ lnðx kc þ 0:5Þ=ðn kc À x kc þ 0:5Þ and find the sample variance of kt s is 0.947 and the sample variance of kc s is 0.703. We then conducted the robust Brown-Forsythe Levene-type test for equal variances, 24 which does not require the normality assumption. The test does not reject the null at the significance level ¼ 0:05. We also computed the average sample size ratio between the treatment and control and find R ¼ 1:64. Thus, we believe MI data may fit in one of the simulation settings for small sample sizes with w ¼ 0.5, R ¼ 2, ¼ 0 or 0.5, and K ¼ 50. Note that for the adverse effect, should be nonnegative since a negative actually means the effect is beneficial instead, which is difficult to interpret.
MI data
According to Figure 2 (a), SA_1 consistently underestimate when ! 0, which might explain its negative estimate for the MI data. Based on Table 1 , regardless of the values, SA_0.25 and MH are the least biased for w ¼ 0.5. However, there is a small chance that w < 0.5. Although the Levene's test does not reject equal variances, the treatment appears to have heavier tails and so a larger variance than the control, as shown in the left panel of Figure 3 , which plots the empirical density curves of the estimated log odds for MI data. As MH severely overestimates when w < 0.5, we leave out MH by noting MH does give the largest positive estimate among all; we select SA_0.25 as a much safer choice because SA_0.25 performs consistently well in terms of bias regardless of the , w values. As to MSE, for R ¼ 2 and ¼ 0, 0:5, iMUE and DSL are the most efficient for w ¼ 0.5 and w ¼ 0, respectively. Besides, SA_0.25 and iMUE are the best two methods in terms of type I error and 95% CI coverage for these settings. The three estimators, SA_0.25, iMUE, and DSL, all give small positive estimates for , with CIs covering 1, which supports the conclusion that the (small positive) effect of rosiglitazone on MI is not statistically significant.
CVD data
As shown in Table 4 for the CVD data, SA_0.5 and SA_1 give slightly negative estimates while the other methods report positive estimates; and all the CIs cover 1, which indicates that all the different methods unanimously conclude the effect of rosiglitazone on CVD is not statistically significant.
The right panel of Figure 3 shows that the empirical density curve of the log odds for the treatment has much wider tails than that for the control. The sample variance of kt s is 0.823 and that of kc s is 0.474. The BrownForsythe test for equal variances returns a p-value 0.040, suggesting that the variance of the treatment is larger. Thus, we believe CVD data may fit in one of the simulation settings for small sample sizes with w ¼ 0, R ¼ 2, ¼ 0 or 0.5, and K ¼ 50. For these settings, Table 1 suggests that GLMM and iMUE are the least biased; Table 2 suggests that DSL is the most efficient; and Table S2 and Figure S6 suggest that SA_0.25, iMUE, GLMM, and DSL work well in terms of the type I error and 95% CI coverage. All the four methods report positive estimates, and iMUE, DSL, and SA_0.25 all suggest that the effect is pretty close to zero. Thus, we believe there is no strong evidence to support the existence of the rosiglitazone effect on CVD.
Discussion
In the context of meta-analysis of rare binary events, we have proposed a general framework for RE models, which requires minimal assumptions. We have conducted a comprehensive simulation study to compare the performance of various estimators in terms of bias, MSE, type I error, and CI coverage. We find that for large samples, SA_0.5 performs very well: it is the least biased in nearly all the settings examined; it is the most efficient in some settings and always among the most efficient group otherwise; and it has good performance on the type I error and coverage rate as well. We also find iMUE and SA_0.25 perform quite well for large samples in terms of all the four measures. In addition, SA_1 can achieve the minimum MSE in some of the settings, which confirms our theoretical results in ''MSE'' section.
For small samples, the variability direction (i.e. which group has larger variability) plays an important role in selecting the least biased method(s), as indicated by Table 1 . In situations when there is no or vague information about the direction, we recommend SA_0.25 because it is always among the least biased group if it is not the best. As to MSE, the choice of the most efficient methods depends on the variability direction and the sample size ratio between the treatment and control, as well as the effect size, as summarized in Table 2 . When such information is not available or partially available, we should select a safe choice (e.g. SA_0.25) and avoid methods (e.g. EL, MH, SA_1) that can perform well only in some specific conditions but have very large MSE in neighboring conditions. In addition, our finding that SA_0.25 and iMUE perform well in terms of type I error and CI coverage for small sample sizes can also help us make a wise decision.
Through a data example involving rosiglitazone meta-analysis, we have illustrated how to choose appropriate methods according to the above guidelines, combined with exploratory analysis. It is worth mentioning that our conclusions about the rosiglitazone effect on MI and CVD support the action that the U.S. Food and Drug Administration (FDA) lifted its earlier restrictions on rosiglitazone in 2013. Our finding that the variability direction has a large impact on the small-sample performance may indicate a future research direction. For the purpose of simulation, we have proposed a flexible RE model (7) . It would be interesting to develop novel statistical methods for estimating and testing the treatment effect based on this RE model, which can formally account for unequal group variability to improve the inference for small samples.
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